VYNE Therapeutics declares positive phase 1a SAD data for VYN202, a novel BD2-selective BET inhibitor

VYNE Therapeutics Inc. announced promising results from the single ascending dose (SAD) phase of its phase 1a trial for VYN202, an innovative oral BET inhibitor. This two-part, double-blind, placebo-controlled study evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of VYN202 in healthy volunteers.

Key findings include:

1.  VYN202 was well tolerated across all dose groups, with no serious or drug-related adverse events.

2.  Plasma and urine concentrations of VYN202 increased in a dose-dependent manner.

3.  Blood tests indicated increased HEXIM1 protein levels, suggesting effective target engagement, along with inhibitory effects on inflammatory biomarkers related to psoriasis and rheumatoid arthritis.

The phase 1a multiple ascending dose (MAD) portion has begun, focusing on safety and PK over 14 days. Results are expected in Q4 2024. VYNE aims to develop differentiated therapies for chronic inflammatory conditions through its InhiBET platform.